BioNTech plans a new regional headquarter in Singapore and will also build a manufacturing facility that will produce its mRNA vaccine.
According to the company, the facility could be operational as early as 2023. It would allow the firm to scale up production for Southeast Asia to address future pandemic threats.
BioNTech’s expansion is supported by the Singapore Economic Development Board — a government agency under the trade ministry. The venture is expected to create up to 80 additional jobs in the country.
“Having multiple nodes in our production network is an important strategic step in building out our global footprint and capabilities,” Ugur Sahin, CEO, and Co-founder of BioNTech said in a statement.
“With this planned mRNA production facility, we will increase our overall network capacity and expand our ability to manufacture and deliver our mRNA vaccines and therapies to people around the world.”
In line with BioNTech’s mission to develop next-generation immunotherapies to improve the health of individuals worldwide, the new mRNA manufacturing facility will leverage cutting-edge manufacturing and digital infrastructure. It will be equipped to produce a range of novel mRNA vaccines and therapeutics for infectious diseases and cancer. The envisioned site will bring highly automated and end-to-end mRNA production capabilities across drug substance, drug product, and fill-and-finish, with an estimated annual capacity of several hundred of million doses of mRNA-based vaccines depending on the specific vaccine.
“We strongly welcome BioNTech’s plan to establish its mRNA manufacturing facility and regional headquarters in Singapore. The investment will enable Singapore to develop capabilities in an important new therapeutic modality as part of the strategy to grow our biopharmaceutical industry,” said Dr. Beh Swan Gin, Chairman, EDB. “In particular, BioNTech’s mRNA manufacturing facility will contribute significantly to the region’s ability to address future pandemic threats.”